<DOC>
	<DOC>NCT00044668</DOC>
	<brief_summary>This multi-center, open-label study is designed to examine the effects on long-term glucose control and safety of AC2993 in patients with type 2 diabetes treated with metformin, sulfonylurea, or metformin and sulfonylurea combination.</brief_summary>
	<brief_title>Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Subjects with type 2 diabetes Treated for at least 3 months prior to screening either with metformin, sulfonylurea, or metformin and sulfonylurea combination BMI 2545 kg/m^2 HbA1c between 7.5 % and 12.0 %, inclusive Treated with other oral antidiabetic agents other than metformin and sulfonylureas within 3 months of screening Patients previously treated with AC2993 Patients presently treated with insulin</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>exendin-4</keyword>
	<keyword>diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>